21 November 2020 - The furious race to develop a coronavirus vaccine played out against a presidential election, between a pharmaceutical giant and a biotech upstart, with the stakes as high as they could get.

The call was tense, the message discouraging. Moncef Slaoui, the head of the Trump administration’s effort to quickly produce a vaccine for the coronavirus, was on the phone at 6 p.m. on 25 August to tell the upstart biotech firm Moderna that it had to slow the final stage of testing its vaccine in humans.

Read New York Times article